Novartis has discontinued two undisclosed programs under its current partership with Voyager, the biotech announced last month. Projects under the deal for spinal muscular atrophy and Huntington’s ...
- Additional new data demonstrate VY-TAU01, Voyager’s lead antibody targeting pathological tau, was well-tolerated and demonstrated favorable pharmacokinetics in non-human primates (NHPs) - - Data to ...
Neurology biotech Voyager Therapeutics has laid off 30 employees, a spokesperson for the Massachusetts-based company confirmed to Fierce Biotech. The layoffs come after the November announcement, ...
Voyager 1 and 2 have traveled billions of miles over nearly half a century. NASA intends the Voyager program to continue its historic exploration for at least another few years. But after nearly half ...
- New program combines IV-delivered TRACER™ capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the protective APOE2 variant - - Voyager’s ...
Single dose of TRACER AAV vector encoding anti-HER2 antibody reduced CNS tumor burden and extended survival across multiple mouse models of breast cancer brain metastasis Novel AAV5-derived capsid ...
LEXINGTON, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it has decided to ...
The Voyager program is an ongoing American scientific program that employs two robotic interstellar probes, Voyager 1 and Voyager 2. They were launched in 1977 to take advantage of a favorable ...
NPR's Lulu Garcia-Navarro talks to Ed Stone, a chief scientist at NASA, about the Voyager program as it approaches its 40th anniversary. He's 81 years old and has spent half his life on the project.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback